Amayrani Cano-Zaragoza

Amayrani Cano-Zaragoza

Auto-generated profile, based on publicly available information

Amayrani Cano-Zaragoza

Unidad de Investigación Médica en Enfermedades Endócrinas, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social , Mexico City, 06720

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2023 in Archives of Medical Research
Verified
Journal Article
Closed access
JKJacobo Kerbel
Jacobo Kerbel
ACAmayrani Cano-Zaragoza
Amayrani Cano-Zaragoza
RERodrigo Espinosa-Dorado
Rodrigo Espinosa-Dorado
KTKeren-Enid García de la Torre
Keren-Enid García de la Torre
MMMoises Mercado
Moises Mercado

18 November 2023 in Archives of Medical Research
Verified
Journal Article
Closed access
DMDaniel Marrero-Rodríguez
Daniel Marrero-Rodríguez
SVSandra Vela-Patiño
Sandra Vela-Patiño
FMFlorencia Martinez-Mendoza
Florencia Martinez-Mendoza
AVAna Valenzuela-Pérez
Ana Valenzuela-Pérez
EPEduardo Peña-Martínez
Eduardo Peña-Martínez
MMMoises Mercado
Moises Mercado

9 April 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
Daniel Marrero-RodriguezDaniel Marrero-Rodriguez
Daniel Marrero-Rodriguez
VCVictor A Cortes-Morales
Victor A Cortes-Morales
ACAmayrani Cano-Zaragoza
Amayrani Cano-Zaragoza
FMFlorencia Martinez-Mendoza
Florencia Martinez-Mendoza
JKJacobo Kerbel-Suton
Jacobo Kerbel-Suton
MMMoises Mercado
Moises Mercado
Context: The tumor microenvironment (TME) includes diverse cellular components such as mesenchymal stem cells (MSCs) and immune cells, among others. MSC have been isolated from different tumors and they favor tumor cell growth; however, their role in pituitary tumors (PTs) remains unknown. Objective: Herein we report the presence of MSCs in 2 adrenocorticotropin (ACTH)-secreting PTs causing Cushing disease (MCU), 2 nonfunctioning adenomas of gonadotrope differentiation (MNF), and 2 nontumoral pituitary glands (MS). Methods: We have analyzed the transcriptomic profiles by RNA sequencing and compared MSCs in terms of their immunosuppressive effects against lymphoid T-cell and macrophage populations by means of cocultures and flow cytometry. Results: Our transcriptomic analysis revealed molecular differences between MSCs derived from nontumoral pituitaries and MSCs derived from PTs. Two distinct subpopulations of MSC emerged: one displaying immunosuppressive properties and the other with increased proproliferative capabilities, regardless of their origin. MSCs derived from ACTH- and nonfunctioning PTs, but not those derived from nontumoral glands, significantly inhibited the proliferation of activated T cells, favored the generation of regulatory T cells, and promoted M2 macrophage polarization. Such immunosuppressive effects were correlated with an upregulation of programmed death ligand 1 and intracellular expression of macrophage colony-stimulating factor (M-CSF) and interleukin-10. Importantly, MSC derived from ACTH-PTs showed a higher immunosuppressive potential than MSC isolated from nonfunctioning tumors. Conclusion: This study demonstrates the presence of at least 2 MSC subpopulations in the pituitary gland and suggests that immunosuppressive effects of MSCs may have important implications in PT growth.

17 February 2023 in JCEM Case Reports
Verified
Journal Article
Open access
PDF file
KGKeren-Sandyn García-De-La-Torre
Keren-Sandyn García-De-La-Torre
JKJacobo Kerbel
Jacobo Kerbel
ACAmayrani Cano-Zaragoza
Amayrani Cano-Zaragoza
MMMoises Mercado
Moises Mercado
Acromegaly/giantism results from the chronic excess of growth hormone (GH) and insulin-like growth factor-1 (IGF-1), in more than 96% of cases, due to a GH-secreting pituitary adenoma. Primary treatment of choice is transsphenoidal resection of the adenoma. More than 30% to 40% of operated cases require adjunctive forms of treatment, be it pharmacological or radiotherapeutical. The multimodal treatment of acromegaly has resulted in substantial improvements in the quality of life and life expectancy of these patients. We herein present the complex case of a patient with acromegaly due to a mammosomatotrope adenoma, with a germ-line AIP (aryl hydrocarbon receptor–interacting protein) mutation, who had a chronic and protracted course of more than 15 years during which he was treated with surgery, somatostatin receptor ligands, dopamine agonist, and the GH receptor antagonist pegvisomant. At one point, he was able to come off medications and was even found to be transiently GH-deficient, only to develop acromegaly again after a couple of years.